Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer
| Autor: | Xiaoyu Teng, Shusen Wang, Yuting Tan, Dong-Geng Liu, Ying Jin, Xiuyu Cai, Xin An, Roujun Peng, Zhongyu Yuan, Yanxia Shi, Ye Cao, Yue-Li Sun |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 Antineoplastic Agents Breast Neoplasms Kaplan-Meier Estimate Antibodies Monoclonal Humanized Disease-Free Survival Trastuzumab Internal medicine Odds Ratio medicine Clinical endpoint Humans skin and connective tissue diseases neoplasms Aged Retrospective Studies Hematology business.industry Standard treatment Cancer Retrospective cohort study General Medicine Odds ratio Middle Aged medicine.disease Monoclonal Female business medicine.drug |
| Zdroj: | Medical Oncology. 29:39-47 |
| ISSN: | 1559-131X 1357-0560 |
| Popis: | Trastuzumab has been the standard treatment in first-line treatment of HER-2-positive advanced breast cancer (H2ABC). This study explored whether the delayed and repeated use of trastuzumab could influence overall survival (OS). A total of 128 patients with H2ABC who had received at least one line of trastuzumab-based regimens were included. The primary endpoint was OS defined as from the date of first diagnosis of H2ABC to death. The median OS of initiating trastuzumab in first-line group (n = 56), in the second-line group (n = 32), and the third- or more-line group (n = 40) was 40.6 m, 39.5 m, and 38 m, respectively (P = 0.867). For patients who had received over one line of trastuzumab (n = 46), the median OS was 44 m, and for those receiving only one line (n = 67), it was 27.6 m (P = 0.059). The delayed use of trastuzumab has no negative effect on the OS of patients with H2ABC. There is a trend of improved OS over the repeated use of trastuzumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink